Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder

  • End date
    Dec 21, 2032
  • participants needed
  • sponsor
    Hospital de Clinicas de Porto Alegre
Updated on 21 January 2021
psychiatric disorder
attention deficit disorder


Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.


Methylphenidate (MPH) is the most prescribed psychostimulant for children and adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Meta-analyses and systematic reviews have shown that MPH is safe and efficacious in attenuating the core symptoms of ADHD, promoting overall clinical improvement. However, many patients still do not show an appropriate clinical response to the MPH treatment and there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. Therefore, it is essential to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.

Condition Oppositional Defiant Disorder, Oppositional Defiant Disorder (ODD), Attention deficit hyperactivity disorder, Attention Deficit/Hyperactivity Disorder (ADHD - Pediatric), Attention Deficit/Hyperactivity Disorder (ADHD - Adults), Family Medicine-ADHD Pediatrics, Attention Deficit/Hyperactivity Disorder (ADHD - Adults), Attention Deficit/Hyperactivity Disorder (ADHD - Pediatric), Oppositional Defiant Disorder (ODD), Family Medicine-ADHD Pediatrics, adhd
Treatment Immediate-release Methylphenidate
Clinical Study IdentifierNCT02951754
SponsorHospital de Clinicas de Porto Alegre
Last Modified on21 January 2021


Yes No Not Sure

Inclusion Criteria

White Brazilian of European descent
Fulfillment of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) diagnostic criteria for ADHD
Eligibility to immediate-release MPH (IR-MPH) treatment

Exclusion Criteria

Contraindication for IR-MPH use
Current stimulant treatment
Evidence of a clinically significant neurological disease that might affect cognition (e.g., delirium, dementia, epilepsy, head trauma, and multiple sclerosis)
Current or past history of psychosis
Estimated intelligence quotient score lower than 70
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note